Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perfluorohexyloctane for post-LASIK dry eye disease
ChiCTR2600132150Phase 4Not yet recruiting
- Sponsor
- Dalian He Eye Hospital
- Start
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of perfluorohexyloctane and sodium hyaluronate in dry eye syndrome (DED) (2 arms), sponsored by Dalian He Eye Hospital. Primary endpoint: Non-invasive tear film breakup time at 4 weeks. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
perfluorohexyloctanesodium hyaluronate
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on ChiCTR2600132150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132150.